CompletedPhase 3NCT00053053
Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer
Studying Adult T-cell leukemia/lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Radiation Therapy Oncology Group
- Principal Investigator
- Lawrence B. Berk, MD, PhDCCOP - Columbus
- Intervention
- Juven(dietary_supplement)
- Enrollment
- 472 enrolled
- Eligibility
- 17-120 years · All sexes
- Timeline
- 2002 – 2009
Study locations (30)
- Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States
- Comprehensive Cancer Institute, Huntsville, Alabama, United States
- MBCCOP - Gulf Coast, Mobile, Alabama, United States
- Montgomery Cancer Center, Montgomery, Alabama, United States
- DCH Cancer Treatment Center, Tuscaloosa, Alabama, United States
- Foundation for Cancer Research and Education, Phoenix, Arizona, United States
- Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States
- Mount Diablo Regional Cancer Center, Concord, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- California Cancer Center - Woodward Park Office, Fresno, California, United States
- Saint Agnes Cancer Center, Fresno, California, United States
- Sutter Health Western Division Cancer Research Group, Greenbrae, California, United States
- Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States
- Veterans Affairs Medical Center - Long Beach, Long Beach, California, United States
- USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00053053 on ClinicalTrials.govOther trials for Adult T-cell leukemia/lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT05745714HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesPrincess Maxima Center for Pediatric Oncology
- RECRUITINGPHASE2NCT07159620Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like PatientsThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE1NCT07108868A Phase I Dose Finding Study of MB-CART2219.1University Hospital Tuebingen
- RECRUITINGNCT05237986Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell TherapyNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT07008885BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALLChinese PLA General Hospital
- ACTIVE NOT RECRUITINGPHASE3NCT07541755PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALLFujian Medical University Union Hospital
- RECRUITINGPHASE2NCT06698003A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1Memorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2NCT06598722BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine